Geron Profile

5.46
USD 0.74  11.94%
5%
14%

Exercise or conversion by Stephen Rosenfield of 36000 shares of Geron subject to Rule 16b-3

Geron Corporation insider trading alert for exercise of stock option (right to buy) by Stephen Rosenfield, EVP Genl Counsel & Secretary, on September 12, 2018. This event was filed by Geron Corp with SEC on 2018-08-24. Statement of changes in beneficial ownership - SEC Form 4. Stephen Rosenfield is currently serves as executive vice president general counsel and corporate secretary of Geron [view details]   

Geron Summary

Geron Corporation (GERN) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 15 people. Geron is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 1000 M. Geron Corporation conducts business under Healthcare sector and is part of Biotechnology industry. This company has 183.62 M outstanding shares of which 62.9 M shares are currently shorted by private and institutional investors with about 9.73 trading days to cover. GERON CORP currently holds about 160.93 M in cash with (11.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.88.
Check Geron Probability Of Bankruptcy

Ownership Allocation (%)

Geron Target Price Odds Analysis

Odds Below 5.46HorizonTargetOdds Above 5.46
30.09%30 days 5.46 69.72%
Based on normal probability distribution, the odds of Geron to move above current price in 30 days from now is about 69.72% (This Geron Corporation probability density function shows the probability of Geron Stock to fall within a particular range of prices over 30 days) .

Geron Top Holders

Geron Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Fmr LlcCommon Shares15.6 M53.4 M
State Street CorpCommon Shares15.5 M53.2 M
Perceptive Advisors LlcPut Options2.4 M2.9 M
Group One Trading LpCall Options582.7 K2 M
View Geron Diagnostics

Geron Corporation Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Geron Key Fundamentals

Geron Against Markets

Geron Current Ratings

Geron Corporation 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
16 
Chance of
Financial Distress (0 to 100%)
72 
Equity ratings for Geron Corporation are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California. Geron operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 15 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Geron SEC Filings
Geron SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameGeron Corporation
President CEO, DirectorJohn ScarlettView All
Thematic Classification
Currently Active Investing Idea
Cancer Fighters
  Cancer Fighters
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationCALIFORNIA U.S.A
Business Address149 Commonwealth Drive
ExchangeBATS Exchange
CIK Number0000886744
CUSIP037416310
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.geron.com
Phone650 473 7700
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2019
Most Recent QuarterJune 30, 2018
Last Fiscal Year EndDecember 31, 2017
Date Short InterestAugust 31, 2018

Geron Directors

Geron Corporate Directors

Daniel Bradbury Independent Director
Robert Spiegel Independent Director
Karin Eastham Independent Director
Please also check Risk vs Return Analysis. Please also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. drill down to check world indexes.
Search macroaxis.com